Cara Therapeutics, Inc .has announced positive results from its Human Abuse Liability trial of an intravenous formulation of CR845, a first-in-class peripherally-selective kappa opioid agonist. “We are extremely pleased with the results from this human abuse liability trial, which suggest the potential for CR845 to be the first Schedule V or non-scheduled peripheral opioid for acute pain,” said Derek Chalmers, Ph.D, D.Sc., President and Chief Executive Officer of Cara Therapeutics … more

Earlier in the month, Cara announced the unexpected death of its Chief Medical Officer … more